Dermata Therapeutics(DRMA) - 2024 Q2 - Quarterly Results

EX-99.1 2 drma_ex991.htm PRESS RELEASE EXHIBIT 99.1 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients - - Dermata continues discussions with potential botulinum toxin partners for DMT410 – - Raised $2.3 million in net proceeds from financing completed in 2Q 2024 - SAN DIEGO, CA, August 7, 2024 – Dermata Therapeutics, Inc. (Nasdaq: DRMA; DRMAW) ("Derma ...